SCHEDULE: Citadel Group Updates Arvinas Stake to 0.4%
Beneficial Ownership Disclosure
Citadel and its affiliates, including Kenneth Griffin, have filed an amended Schedule 13G, updating their beneficial ownership in Arvinas, Inc. to a combined 0.4%.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively reported beneficial ownership of 143,315 shares of Arvinas, Inc. common stock, representing 0.2% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively reported beneficial ownership of 120,928 shares of Arvinas, Inc. common stock, also representing 0.2% of the class.
- Kenneth Griffin, through his controlling interests in the various Citadel entities, is deemed to beneficially own an aggregate of 264,243 shares, which constitutes 0.4% of Arvinas, Inc.'s outstanding common stock.
- All reported shares are held with shared voting and shared dispositive power, with no sole voting or dispositive power indicated for any reporting person.
- The percentages are based on 73,417,595 shares of Arvinas, Inc. common stock outstanding as of August 1, 2025, as reported in the issuer's Form 10-Q filed on August 6, 2025.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G Amendment) and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
Arvinas, Inc. operates in the biotechnology sector, focusing on protein degradation. Institutional ownership disclosures like this Schedule 13G are common for publicly traded companies in this industry, reflecting investment activity by major financial firms.
Stakeholder Impact
- Shareholders: Disclosure of institutional ownership provides transparency regarding significant holders and their updated positions in the company.
Key Dates
| Date | Description |
|---|---|
| 08/01/2025 | Date as of which the number of outstanding shares (73,417,595) was determined for percentage calculation. |
| 08/06/2025 | Date the issuer's Form 10-Q was filed, providing the shares outstanding data. |
| 09/30/2025 | Date of the event which required the filing of this statement. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Arvinas Inc., Citadel Advisors, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.